Cell Therapy Could Replace Need for Kidney Transplants
Wake Forest Institute for Regenerative Medicine (WFIRM) scientists are working on a promising approach for treating chronic kidney disease—regeneration of damaged tissues using therapeutic cells.
Bioengineered BioMask Offers Hope for Healing Facial Skin Injuries
Facial wounds or burns could one day be treated with skin tissue regenerated with the use of a 3-D bioprinted BioMask created by Wake Forest Institute for Regenerative Medicine (WFIRM) scientists.
NIH Grant to Fund Study of Deep Brain Stimulation for Alzheimer's
Wake Forest Baptist Health scientists have been awarded $3.9 million from the National Institutes of Health to determine if a procedure used to treat Parkinson’s patients can improve age-related cognitive abilities and counteract the effects of Alzheimer’s and other types of dementia.
Lowering Blood Pressure Reduces Risk of Cognitive Impairment
Intensive control of blood pressure in older people significantly reduced the risk of developing mild cognitive impairment (MCI), a precursor of early dementia, in a clinical trial led by scientists at Wake Forest Baptist Health.
Gut Microbiome May Affect Some Anti-diabetes Drugs
Bacteria that make up the gut microbiome may be the reason why orally administered drugs for diabetes work for some people but not others, according to Wake Forest Baptist Health researchers.
First-ever Model Developed for Patient-specific Treatment of Appendix Cancer
Scientists at the Wake Forest Institute for Regenerative Medicine (WFIRM) have developed a process that could change the way cancer of the appendix is treated.
Anti-Leprosy Drug Shows Promise as Multiple Myeloma Treatment
Although several drugs are used to treat multiple myeloma (MM), a research team at Wake Forest Baptist Health may have found an effective new drug.
Return to Summer 3019 Table of Contents
Research reported on in this publication was supported by the following grants from the National Institutes of Health (NIH):
Bioengineered BioMask Offers Hope for Healing Facial Skin Injuries: NIH grant 1P41EB023833-01.
NIH Grant to Fund Study of Deep Brain Stimulation for Alzheimer’s: National Institute of Aging grant 1R01AG060754-01A1.
Researchers Identify Novel Molecular Mechanism Involved in Alzheimer’s: NIH grants K99/R00 AG044469, R01 AG055581, R01 AG056622, F31AG055264, F31AG054113, P50AG005136, U01AG006781; also Alzheimer’s Association grant NIRG-15-362799, BrightFocus Foundation grant A2017457S, Wake Forest Alzheimer’s Disease Core Center pilot grant P30AG049638, Wake Forest Clinical and Translational Science Institute pilot grant, and the Nancy and Buster Alvord Endowment.
Lowering Blood Pressure Reduces Risk of Cognitive Impairment: NIH contract numbers HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN268200900048C, and HHSN268200900049C, and interagency agreement A-HL-13-002-001; clinical trial number: NCT01206062.
First-ever Model Developed for Patient-specific Treatment of Appendix Cancer: A Wake Forest Clinical and Translational Science Institute Pilot Award (NIH UL1 TR001420); also internal funding from the Comprehensive Cancer Center at Wake Forest Baptist Health.
Anti-leprosy Drug Shows Promise as Multiple Myeloma Treatment: NIH grants CA220096, CA224434, CA193981 and CA190533; a Ruth L. Kirschstein National Research Service Award F32CA189622; NIH grants CA197996, 1F99CA21245501, R01AI100157 and R01CA121044; the Jennifer Linscott Tietgen Foundation; and in part by a National Cancer Institute Cancer Center Support Grant P30CA16056 to the Roswell Park Comprehensive Cancer Center, for the Clinical Data Network and the Animal Facility.